Biologics Outsourcing Global Market - Forecast to 2025

  • ID: 4375383
  • Report
  • Region: Global
  • 527 Pages
  • IQ4I Research & Consultancy Pvt. Ltd
1 of 5
The Biologics Outsourcing Global Market is Expected to Grow at Double Digit CAGR to Reach $70.3 Billion by 2025

FEATURED COMPANIES

  • Abbvie
  • Bioconnect Life Sciences
  • Curaxys
  • Immunoreagents
  • Neu Encepharm Gmbh
  • Sbh Sciences, Inc.
  • MORE

The biologics outsourcing global market is expected to grow at double digit CAGR to reach $70.3 billion by 2025. Biologics are therapeutic entities composed of sugars, proteins, or nucleic acids made from natural sources such as human, animal or micro organisms. Biologics can also include live attenuated microorganisms (vaccines), allergenic extracts (allergy shots), human cells and tissues (transplantation), cell therapies and gene therapies. Like small molecule drugs, these drugs are intended for treatment of diseases and medical conditions. However, Biologics bring into picture higher range of specificity in treating a disease condition as the biologic entities like monoclonal antibodies and recombinant proteins target specific areas in the molecular mechanism of disease action.

Although biologics are much costlier than small molecule drugs, these classes of drugs prove to be highly beneficial for the patient and also bring about 40% higher profit to the manufacturers when compared to small molecule drug treatments. Due to the increasing demand for biologics drugs and increased regulatory approvals for these drugs, there is huge demand for biologics manufacture and testing at various levels of clinical studies as well as commercial supply. The Large Biopharma companies are coming up with strategies to cut down on their operational costs and concentrate more on their core competencies by outsourcing this piece of work to contract research organizations (CROs), contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs). These organizations bridge the gap between demand and supply and ensure the drug discovery process gets much faster and convenient thus bringing life saving drugs to the market to reach the needy patients.

The biologics outsourcing global market is estimated region wise with various drug discovery, development and manufacturing segments and their market shares. This section also included the market sizing of antibodies, recombinant proteins, vaccines, and others which included gene therapy, cell therapy. The emerging trends and strategies adopted by global biopharmaceutical companies and their impact on outsourcing market were discussed. A list of approved drugs (2012-2016) along with phase wise pipeline analysis for biologics was included.

  • In depth assessment of all segments and sub segments of Biologics Outsourcing global market
  • Regional analysis of biologics outsourcing global market
  • Market sizing based on type of Biologics, Therapeutic areas and end users
  • Emerging trends and strategies
  • A list of approved drugs (2012-2016) along with phase wise and modality based pipeline analysis for biologics
  • Market share analysis of major players in biologics outsourcing global market
  • Biologics services cost analysis for various modalities
  • Service provider matrix based on service offerings, revenues and employee size
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbvie
  • Bioconnect Life Sciences
  • Curaxys
  • Immunoreagents
  • Neu Encepharm Gmbh
  • Sbh Sciences, Inc.
  • MORE

1 Biologics Outsourcing Global Market
1.1 Introduction
1.2 Landscape of Biologics Market
1.3 Biologics Global Market
1.3.1 North America
1.3.2 Asia Pacific
1.4 China Biologics Outsourcing Market
1.5 China Vs India - Biologics Market
1.5.1 Regulations and Government Initiatives
1.5.2 Capabilities and Technologies

2 Market Analysis
2.1 Introduction
2.2 Factors Influencing Market
2.2.1 Drivers and Opportunities
2.2.1.1 Increased Investment in R&D by Pharmaceutical Companies is Increasing the Outsourcing
2.2.1.2 Adoption of Biological Therapies in Disease Management
2.2.1.3 Successful Collaboration and Low Cost for Outsourcing
2.2.1.4 Increasing Biologics Approvals in the Past Year
2.2.1.5 Increasing Chronic and Autoimmune Illnesses
2.2.1.6 Increasing Number of Branded Drugs Going Off-Patent Creates a Scope for Biosimilars
2.2.1.7 Requirement of Novel Biologics Therapeutics for Certain Diseases
2.2.1.8 Increasing Demand for Antibody Conjugates and Bispecific Antibodies
2.2.1.9 Advanced Technologies for Screening, Cell Line Engineering and Bioprocessing
2.2.1.10 Pharma Companies Restricting Their Global Presence, Reducing Manpower, Lack of Facilities for Discovery and Manufacturing of Biologics
2.2.2 Restraints and Threats
2.2.2.1 Intense Complexities in Handling Biologics
2.2.2.2 Requirement of Highly Skilled Technicians
2.2.2.3 High Cost of Drug Development Process
2.2.2.4 Challenges in Oral Formulations With Biologics
2.2.2.5 Stringent Regulatory Frameworks
2.2.2.6 High Capital and Technical Requirements to Obtain Gmp Certifications
2.2.2.7 Limited IP Protection in Developing Regions
2.2.2.8 High Chances of End Stage Failure of Drug
2.2.2.9 Conflict of Interest Between Pharmaceutical Company and Cro

3 Biologics Outsourcing Global Market, Market Analysis
3.1 Introduction
3.2 Discovery and Pre-Clinical Development Process
3.3 Biologics Outsourcing Global Market, by Product Type
3.3.1 Antibody
3.3.1.1 Monoclonal Antibody
3.3.1.2 Bispecific Antibody
3.3.1.3 Antibody Drug Conjugates
3.3.1.4 Others
3.3.2 Recombinant Protein
3.3.3 Vaccines
3.3.4 Others
3.3.4.1 Gene Therapy
3.3.4.2 Cell Therapy
3.3.4.3 Others
3.4 Market Share Analysis
3.5 Company Developments
3.5.1 Agreements, Partnerships & Collaborations
3.5.2 Acquisitions
3.5.3 New Service Launch
3.5.4 Other Developments
3.6 Service Cost Analysis
3.6.1 Antibody Production Service Costs
3.6.2 Custom Monoclonal Antibody Production Service Costs
3.6.3 Custom Polyclonal Antibody Production Service Costs
3.6.4 Protein Production Service Costs
3.6.5 Additional Antibody and Protein Services
3.6.6 Gene Editting Services
3.6.7 Car-T/Nk Platform Services

4 Biologics Outsourcing Global Market - Animal Model Services
4.1 Introduction
4.1.1 Comparison Matrix of Animal Models and Applications
4.1.2 Small Animal Models
4.1.3 Large Animal Models
4.2 Ethics and Regulations
4.3 Alternatives to Animal Models
4.4 Overview of Applications of Animal Models
4.5 Market Share Analysis
4.6 Competitive Landscape
4.7 Company Developments

5 Biologics Outsouring Global Market - Biomanufacturing
5.1 Introduction
5.2 Contract Biomanufacturing, by Process
5.2.1 Biomanufacturing by Mammalian Cell Culture
5.2.2 Biomanufacturing by Microbial Cell Culture
5.2.3 Biomanufacturing by Other Cell Culture
5.3 Contract Biomanufacturing Global Market, by End Users
5.3.1 Contract Biomanufacturing of Diagnostics
5.3.2 Contract Biomanufacturing of Research Reagents
5.3.3 Contract Biomanufacturing of Therapeutics
5.4 Contract Biomanufacturing Global Market, by Region
5.5 Competitive Landscape
5.5.1 Capacity Comparison
5.5.2 Contract Manufacturing Global Market Share, by Leading Players
5.6 Company Developments
5.6.1 Merger and Acquisition by Cmos
5.6.2 Collaborations
5.6.3 Capacity Expansions

6 Biologics Outsourcing Global Market - Cell Line Development
6.1 Introduction
6.1.1 Market Dynamics
6.2 Cell Line Development
6.3 Host Cell Lines
6.4 Cell Line Development Services Market, by Expression System
6.4.1 Microbial Expression Systems
6.4.2 Mammalian Expression System
6.4.3 Others
6.5 Cell Line Development Services, by Cell Type
6.5.1 Cho
6.5.2 Murine/Mouse Myeloma
6.5.3 Baby Hamster Kidney (Bhk) Cells
6.5.4 Hybridoma
6.5.5 Human Embryonic Kidney (Hek) Cells
6.5.6 Human Embryonic Retinal Cells (Per.C6)
6.5.7 Others
6.6 Cell Line Development Services, by Applications
6.6.1 Research
6.6.2 Bioproduction
6.6.3 Diagnostics
6.7 Key Developments
6.8 Market Share Analysis

7 Company Profiles
7.1 Abzena Plc
7.1.1 Overview
7.1.2 Financials
7.1.3 Service Portfolio
7.1.4 Key Developments
7.1.5 SWOT Analysis
7.2 Adimab Llc.
7.2.1 Overview
7.2.2 Financials
7.2.3 Service Portfolio
7.2.4 Key Developments
7.2.5 SWOT Analysis
7.3 Albany Molecular Research Inc
7.3.1 Overview
7.3.2 Financials
7.3.3 Service Portfolio
7.3.4 Key Developments
7.3.5 SWOT Analysis
7.4 Beijing Vital Star Biotechnology Co. Ltd.
7.4.1 Overview
7.4.2 Financials
7.4.3 Service Portfolio
7.4.4 Key Developments
7.4.5 SWOT Analysis
7.5 Boehringer Ingelheim
7.5.1 Overview
7.5.2 Financials
7.5.3 Service Portfolio
7.5.4 Key Developments
7.5.5 SWOT Analysis
7.6 Catalent Inc.
7.6.1 Overview
7.6.2 Financials
7.6.3 Service Portfolio
7.6.4 Key Developments
7.6.5 SWOT Analysis
7.7 Charles River Laboratories
7.7.1 Overview
7.7.2 Financials
7.7.3 Service Portfolio
7.7.4 Key Developments
7.7.5 SWOT Analysis
7.8 Crown Biosciences
7.8.1 Overview
7.8.2 Financials
7.8.3 Service Portfolio
7.8.4 Key Developments
7.8.5 SWOT Analysis
7.9 Genoway
7.9.1 Overview
7.9.2 Financials
7.9.3 Service Portfolio
7.9.4 Key Developments
7.9.5 SWOT Analysis
7.1 Genscript Biotech Corporation
7.10.1 Overview
7.10.2 Financials
7.10.3 Service Portfolio
7.10.4 Key Developments
7.10.5 SWOT Analysis
7.11 Gl Biochem
7.11.1 Overview
7.11.2 Financials
7.11.3 Service Portfolio
7.11.4 Key Developments
7.11.5 SWOT Analysis
7.12 Horizon Discovery Group, Plc
7.12.1 Overview
7.12.2 Financials
7.12.3 Service Portfolio
7.12.4 Key Developments
7.12.5 SWOT Analysis
7.13 Jackson Laboratory
7.13.1 Overview
7.13.2 Financials
7.13.3 Service Portfolio
7.13.4 Key Developments
7.13.5 SWOT Analysis
7.14 Innovent Biologics
7.14.1 Overview
7.14.2 Financials
7.14.3 Service Portfolio
7.14.4 Key Developments
7.14.5 SWOT Analysis
7.15 Jhl Biotech Inc.
7.15.1 Overview
7.15.2 Financials
7.15.3 Service Portfolio
7.15.4 Key Developments
7.15.5 SWOT Analysis
7.16 Joinn Laboratories Co. Ltd
7.16.1 Overview
7.16.2 Financials
7.16.3 Service Portfolio
7.16.4 Key Developments
7.16.5 SWOT Analysis
7.17 Lonza Group
7.17.1 Overview
7.17.2 Financials
7.17.3 Service Portfolio
7.17.4 Key Developments
7.17.5 SWOT Analysis
7.18 Merck Kgaa
7.18.1 Overview
7.18.2 Financials
7.18.3 Product Portfolio
7.18.4 Key Developments
7.18.5 SWOT Analysis
7.19 Patheon N.V.
7.19.1 Overview
7.19.2 Financials
7.19.3 Service Portfolio
7.19.4 Key Developments
7.19.5 SWOT Analysis
7.2 Pharmalegacy Biotechnology
7.20.1 Overview
7.20.2 Financials
7.20.3 Service Portfolio
7.20.4 Key Developments
7.20.5 SWOT Analysis
7.21 Pharmaron
7.21.1 Overview
7.21.2 Financials
7.21.3 Service Portfolio
7.21.4 Key Developments
7.21.5 SWOT Analysis
7.22 Prosci Inc.
7.22.1 Overview
7.22.2 Financials
7.22.3 Service Portfolio
7.22.4 Key Developments
7.22.5 SWOT Analysis
7.23 Proteogenix
7.23.1 Overview
7.23.2 Financials
7.23.3 Service Portfolio
7.23.4 Key Developments
7.23.5 SWOT Analysis
7.24 Psychogenics Inc
7.24.1 Overview
7.24.2 Financials
7.24.3 Service Portfolio
7.24.4 Key Developments
7.24.5 SWOT Analysis
7.25 Selexis Sa
7.25.1 Overview
7.25.2 Financials
7.25.3 Service Portfolio
7.25.4 Key Developments
7.25.5 SWOT Analysis
7.26 Shanghai Medicilon
7.26.1 Overview
7.26.2 Financials
7.26.3 Service Portfolio
7.26.4 Key Developments
7.26.5 SWOT Analysis
7.27 Shangpharma Corporation /Shanghai Chempartner
7.27.1 Overview
7.27.2 Financials
7.27.3 Service Portfolio
7.27.4 Key Developments
7.27.5 SWOT Analysis
7.28 Sino Biological
7.28.1 Overview
7.28.2 Financials
7.28.3 Service Portfolio
7.28.4 Key Developments
7.28.5 SWOT Analysis
7.29 Sundia Meditech Co., Ltd.
7.29.1 Overview
7.29.2 Financials
7.29.3 Service Portfolio
7.29.4 Key Developments
7.29.5 SWOT Analysis
7.3 Syngene International
7.30.1 Overview
7.30.2 Financials
7.30.3 Service Portfolio
7.30.4 Key Developments
7.30.5 SWOT Analysis
7.31 Taconic Biosciences
7.31.1 Overview
7.31.2 Financials
7.31.3 Service Portfolio
7.31.4 Key Developments
7.31.5 SWOT Analysis
7.32 Viva Biotech Ltd.
7.32.1 Overview
7.32.2 Financials
7.32.3 Service Portfolio
7.32.4 Key Developments
7.32.5 SWOT Analysis
7.33 Wuxi Apptec
7.33.1 Overview
7.33.2 Financials
7.33.3 Service Portfolio
7.33.4 Key Developments
7.33.5 SWOT Analysis

List of Tables
Table 1 Biosimilar Projects in China
Table 2 Highlights of the Revised Guidelines
Table 3 Biologics Outsourcing Global Market Revenue, by Region (2015-2025) ($Bn)
Table 4 Biologics Outsourcing Global Market Revenue, by Product (2015-2025) ($Bn)
Table 5 List of Biologics Approved (2012-2016)
Table 6 Biologics Outsourcing Global Market Revenue, by Phase (2015-2025) ($Bn)
Table 7 Antibody Outsourcing Global Market Revenue, by Product Type (2015-2025) ($Bn)
Table 8 Others Global Market Revenue, by Product Type (2015-2025) ($Bn)
Table 9 Biologics Outsourcing Global Market Revenue, by End Users (2015-2025) ($Bn)
Table 10 Agreements, Partnership & Collaboartion (2016-2017)
Table 11 Acquisitions (2016-2017)
Table 12 New Service Launch (2016-2017)
Table 13 Other Developments (2016-2017)
Table 14 Service Comparison Matrix of the Company Based on Biologics Type
Table 15 Comparison Matrix of Animal Models and Applications
Table 16 Major Types of Genetically Engineered and Transplantation Animal Models
Table 17 Typical Preclinical Issues of Biologics
Table 18 Animal Model Service Global Market by Region ($Mn)
Table 19 Animal Model Service Global Market by Type of Animal Species ($Mn)
Table 20 Animal Model Service Global Market by Application ($Mn)
Table 21 Animal Model Service Cost (Development of Transgenic Mouse)
Table 22 Animal Model Service Cost (Based on Disease Models)
Table 23 Animal Model Service Cost (Imaging Service Cost by an Academic Institution)
Table 24 Comparison Matrix of Animal Model Service Companies and Models in Respective Therapeutic Areas
Table 25 Comparison Matrix of Animal Model Service Companies and Models in Respective Immunology/Inflammation Therapeutic Areas
Table 26 Comparison Matrix of Animal Model Service Companies and Models in Respective Fibrosis Therapeutic Areas
Table 27 Company Developments
Table 28 Capacity Comparison of Contract Manufacturing Organizations V’S In-House Capacities (L)
Table 29 Contract Manuacturing Organizations Capacity, by Process (L)
Table 30 Anticancer Drugs Synthesized in Microbial Cell Culture
Table 31 Biomanufacturing Outsourcing Global Market by End Users ($Bn)
Table 32 Second Generation Protein Therapeutics
Table 33 Therapeutic Vaccines in Pipeline
Table 34 Biomanufacturing Outsourcing Global Market by Region ($Bn)
Table 35 Company Comparison Matrix, by Manufacturing Capability
Table 36 Mergers and Acquitions (2015-2017)
Table 37 Collaborations (2016-2017)
Table 38 Capacity Expansions (2016-2017)
Table 39 Cell Line Development Services Market, by Region, (2015-2025) ($Mn)
Table 40 Approved Biologics and Cell Line Type (2012-2016)
Table 41 Number of Approved Biologics by Cell Line Type (2012-2016)
Table 42 Cell Line Development Services Market, by Expression System, (2015-2025) ($Mn)
Table 43 Cell Line Development Services Market, by Cell Type, (2015-2025) ($Mn)
Table 44 Cell Line Type of Some Approved Biologics Modalities and Cell Line Type
Table 45 Cell Line Development Services Market, by Application, (2015-2025) ($Mn)
Table 46 Cell Line Development Technologies
Table 47 Cell Line Development Services Cost
Table 48 Key Developments (2015-2017)
Table 49 Comparison Matrix of Cell Line Development Players and Services Offered
Table 50 Abzena Plc: Total Revenue and R&D Expenses (2014-2016) ($Mn)
Table 51 Abzena Plc: Total Revenue, by Segment, (2014-2016) ($Mn)
Table 52 Albany Molecular Research Inc: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 53 Albany Molecular Research Inc: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 54 Albany Molecular Research: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 55 Boehringer Ingelheim: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 56 Boehringer Ingelheim: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 57 Boehringer Ingelheim: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 58 Catalent Inc: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 59 Catalent Inc: Total Revenue, by Segment, (2014-2016) ($Mn)
Table 60 Catalent Inc: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 61 Charles River Laboratories: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 62 Charles River Laboratories: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 63 Charles River Laboratories: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 64 Genoway: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 65 Genscript Biotech Corporation: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 66 Genscript Biotech Corporation: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 67 Genscript Biotech Corporation: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 68 Horizon Discovery Group: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 69 Horizon Discovery Group: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 70 Horizon Discovery Group: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 71 Lonza Group: Total Revenue and R&D Expenses (2014-2016) ($Mn)
Table 72 Lonza Group: Total Revenue, by Segment, (2014-2016) ($Mn)
Table 73 Lonza Group: Total Revenue, by Geography (2014-2016) ($Mn)
Table 74 Merck Kgaa: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 75 Merck Kgaa: Total Revenue, by Segments, (2014-2016) ($Mn)
Table 76 Merck Kgaa: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 77 Patheon N.V.: Total Revenue and R&D Expenses (2014-2016) ($Mn)
Table 78 Patheon N.V.: Total Revenue, by Segment, (2014-2016) ($Mn)
Table 79 Shanghai Chempartner: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 80 Syngene International: Total Revenue and R&D Expenses, (2014-2016) ($Mn)
Table 81 Syngene International: Total Revenue, by Geography, (2014-2016) ($Mn)
Table 82 Wuxi Apptec: Total Revenue and R&D Expenses, (2014-2016) ($Mn)

List of Figures
Figure 1 Top Selling Drugs and Approvals, Small Molecules V’S Biologics, 2012-2016
Figure 2 Top 30 Biologics Patent Expiry, 2013-2038 and Rise of Biosimilars
Figure 3 Biologics Pipeline from Preclinical to Registration for Emerging Disease Areas
Figure 4 Outlook of Biologics Global Market (2015-2025)
Figure 5 Outlook of China Biologics and Biologics Outsourcing Market (2015-2025)
Figure 6 China Vs India
Figure 7 Market Dynamics
Figure 8 Biologics Outsourcing Global Market Revenue, by Region (2015-2025) ($Bn)
Figure 9 Biologics Outsourcing Global Market Revenue, by Product, (2016 V’S 2025) ($Bn)
Figure 10 Biologics in Pipeline, by Type (%)
Figure 11 Discovery Biologics Outsourcing Market, by Services 2016 (%)
Figure 12 Discovery Biologics Outsourcing Market, by Service Type, 2016 ($Mn)
Figure 13 Biologics in Pipeline, by Phase (%)
Figure 14 Biologics Outsourcing Global Market Revenue, by Phase (2016 V’S 2025) ($Bn)
Figure 15 Antibody Outsourcing Global Market Share, by Product Type, (2016 V’S 2025) (%)
Figure 16 Others Global Market Share, by Product Type, (2016 V’S 2025) ($Bn)
Figure 17 Biologics Outsourcing Global Market Revenue, by End-Users (2016 V’S 2025) ($Bn)
Figure 18 Biologics Outsourcing Global Market Share Analysis, by Major Players, 2016
Figure 19 Recent Deals in Biologics Outsourcing
Figure 20 Genome Comparison
Figure 21 Drot: Animal Models
Figure 22 Animal Profiles
Figure 23 Common Animal Models
Figure 24 Advantages and Disadvantages of Rodent Models
Figure 25 Advantages and Disadvantages of Nhp
Figure 26 Principles of 3Rs
Figure 27 Percentage of Animals Used in Diffrent Stages of Pharmacutical Development
Figure 28 Animal Model Service Global Market, by Region ($Mn)
Figure 29 Animal Model Service Global Market, by Type of Animal Species ($Mn, %)
Figure 30 Animal Model Service Global Market, by Application ($Mn, %)
Figure 31 Animal Model Service Outsourcing Global Market Share (%)
Figure 32 Company Developments
Figure 33 Market Dynamics of Contract Biomanufacturing Global Market
Figure 34 Industry Pipeline for Small Molecule V’S Biologics
Figure 35 Global Manufacturing Capacity, Cgmp V’S Non-Cgmp, Inhouse V’S Cmo, 2016
Figure 36 Capacity Utilization of Contract Manufacturing Organizations, by Stage (L)
Figure 37 Capacity Comparison of Mammalian, Microbial and Other Culture Systems (L)
Figure 38 Bio-Manufacturing Outsourcing Global Market, by End Users ($Bn)
Figure 39 Outlook of Biologics Cmo Global Market, by Region ($Bn) and Production in Metric Tons, 2016
Figure 40 Capacity Composition of Top 10 Contract Manufacturing Organizations (L)
Figure 41 Market Share Analysis by Contract Manufacturing Major Players, 2016
Figure 42 Key Deals (2016-2017)
Figure 43 Market Dynamics of Cell Line Development
Figure 44 Cell Line Development Services Market, by Region, (2016) ($Mn)
Figure 45 Number of Approved Biologics by Cell Line Type (2012-2016)
Figure 46 Cell Line Development Services Market, by Expression System, (2016 Vs 2025) ($Mn)
Figure 47 Expression Systems of Some Approved Biologics
Figure 48 Cell Line Development Services Market, by Cell Type, (2016 Vs 2025) ($Mn)
Figure 49 Cell Line Type of Some Approved Biologics
Figure 50 Cell Line Type of Some Approved Biologics Modalities and Cell Line Type
Figure 51 Cell Line Development Services Market, by Application, (2016 Vs 2025) ($Mn)
Figure 52 Key Developments of Cell Line Development Market Players, 2015-2017
Figure 53 Market Share Analysis, by Cell Line Development Major Players (2016)
Figure 54 Overview: Abzena Plc
Figure 55 SWOT: Abzena Plc
Figure 56 SWOT: Adimab Llc
Figure 57 Overview: Albany Molecular Research Institute
Figure 58 SWOT: Albany Molecular Research, Inc
Figure 59 SWOT: Beijing Vital Star Biotechnology Co. Ltd.
Figure 60 Boehringer Ingelheim Revenue Overview
Figure 61 SWOT: Boehringer Ingelheim
Figure 62 Overview: Catalent Inc.
Figure 63 SWOT: Catalent Inc.
Figure 64 Overview: Charles River Laboratories
Figure 65 SWOT: Charles River Laboratories
Figure 66 SWOT: Crown Biosciences
Figure 67 Overview: Genoway
Figure 68 SWOT: Genoway
Figure 69 Overview: Genscript Biotech Corporation
Figure 70 SWOT: Genscript Biosciences Corporation
Figure 71 SWOT: Gl Biochem
Figure 72 Overview: Horizon Discovery Group, Plc
Figure 73 SWOT: Horizon Discovery Group, Plc
Figure 74 SWOT: Jackson Laboratory
Figure 75 SWOT: Innovent Biologics
Figure 76 SWOT: Jhl Biotech Inc.
Figure 77 SWOT: Joinn Laboratories Co. Ltd
Figure 78 Overview: Lonza Group
Figure 79 SWOT: Lonza Group
Figure 80 Overview: Merck Kgaa
Figure 81 SWOT: Merck Kgaa
Figure 82 Overview: Patheon N.V.
Figure 83 SWOT: Patheon N.V.
Figure 84 SWOT: Pharmalegacy
Figure 85 SWOT: Pharmaron
Figure 86 SWOT: Prosci. Inc.
Figure 87 SWOT: Proteogenix
Figure 88 SWOT: Psycogenics Inc
Figure 89 SWOT: Selexis Sa
Figure 90 SWOT: Shanghai Medicilon
Figure 91 SWOT: Shanghai Chempartner
Figure 92 SWOT: Sino Biological
Figure 93 SWOT: Sundia Meditech Company Ltd
Figure 94 SWOT: Syngene International
Figure 95 SWOT: Taconic Biosciences
Figure 96 SWOT: Viva Biotech Ltd
Figure 97 SWOT: Wuxi Apptec

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbvie
  • Abeomics
  • Abgenex
  • Abnova
  • Absolute Antibody
  • Abveris Antibody
  • Abzena
  • Accelovance, Inc.
  • Acro Biosystems
  • Adimab
  • Advinus Therapeutics Ltd.
  • Affinity Lifesciences
  • Agc Asahi Glass (Cmc Biologics)
  • Alexion Pharmaceuticals
  • American Preclinical Services
  • Amgen
  • Amplia Pharmatek Inc.
  • Amplycell (Belgium)
  • Amri Inc
  • Anogen
  • Anthem Biosciences
  • Applied Biological Materials (Abmgood)
  • Applied Stem Cell
  • Aragen Biosciences (Gvk Biosciences)
  • Artimmune Sas
  • Atcc
  • Athena Discovery, Inc
  • Atum
  • Avantgen
  • Avastus Preclinical Services
  • Avid Bioservices
  • Bharat Biotech Ltd
  • Binex Co. Ltd.
  • Bioagilytix
  • Bioconnect Life Sciences
  • Biodextris
  • Biogen
  • Biomeostasis
  • Biomere
  • Biomodels Llc.
  • Biospective Inc.
  • Boehringer Ingelheim
  • Bolder Biopath, Inc.
  • Bps Bioscience
  • Bts Research
  • Burleson Research Technologies, Inc.
  • C & M Biolabs
  • Cadila Healthcare Ltd
  • Care Research, Llc
  • Catalent Inc.
  • Cellgenix Gmbh
  • Cellomics Technology
  • Celltrion
  • Celonic
  • Charles River Laboratories
  • Chempartner
  • Chromos Molecular Systems
  • Cobra Biologics
  • Cook Pharmica
  • Covance Research Products
  • Creative Animodel
  • Creative Biolabs
  • Creative Biolabs
  • Crown Bioscience
  • Crucell
  • Curaxys
  • Cyagen Biosciences Inc
  • Cytovance Biologics
  • Dendreon Corporation
  • Diatheva
  • Elabscience
  • Envigo
  • Epimab Biotherapeutics
  • Eurofins
  • Eurogentec
  • Europa Bioproducts
  • Evotec
  • Exonbio
  • Explora Biolabs
  • Fapon
  • Fujifilm Diosynth Biotechnologies
  • Fusion Antibodies
  • G&P Biosciences
  • Gateway Pharmacology Laboratories
  • Gcc Biotech
  • Ge Healthcare Life Sciences
  • Gen Target
  • Genoway
  • Genscript
  • Gigagen Inc
  • Glycotope Gmbh
  • Goodwinbiotechnology
  • Gtc Biotherapeutics
  • Gtp Technology
  • Hera Biolabs
  • Horizon Discovery
  • Immune Technology Corp.
  • Immunoreagents
  • Inficure Bio Ab
  • Inno Biologics
  • Innova Biosciences
  • Innovent Bio
  • Intas Pharma
  • Intestinal Biotech Development
  • Intouch Biosolutions Llc
  • Intrexon
  • Invitek Inc.
  • Invivogen
  • Iontas
  • Jackson Laboratory
  • Jhl Biotech
  • Jsr Corporation (Kbi Biopharma)
  • Jubilant Hollisterstier
  • Kemwell Biopharma
  • Labcorp (Covance)
  • Lakepharma
  • Lampire Biological Laboratories
  • Lancaster University
  • Lfb Biomanufacturing
  • Lonza
  • Luina Bio
  • Mab-Venture
  • Mabplex
  • Md Biosciences Inc.
  • Melior Discovery Inc.
  • Menarini Biotech S.R.L
  • Merck Kgaa
  • Miltenyi Biotech Gmbh
  • Morphotek, Inc., a Subsidiary of Eisai, Inc
  • Murigenics
  • Neu Encepharm Gmbh
  • Neurosolutions Ltd
  • Noble Life Sciences
  • Novasep
  • Novimmune
  • Oak Biosciences
  • Omnia Biologics
  • Oxford Genetics
  • Pairimmune
  • Paragon Bioservices
  • Patheon
  • Pharmacelsus Gmbh
  • Pharmaceutical Product Development
  • Pharmalegacy Laboratories
  • Pharmaron
  • Pharmaseed
  • Physiogenex
  • Polygene Transgenetics
  • Precision Antibody
  • Premas Biotech Pvt Ltd
  • Probiogen
  • Profacgen
  • Promab
  • Proteogenix
  • Proteos Inc
  • Pure Biologics
  • Renovo Neural, Inc.
  • Rentschler Biotech Gmbh
  • Samsung Biologics
  • Sandoz Gmbh
  • Sartorius Stedim Biotech S.A.
  • Sbh Sciences, Inc.
  • Sciquus Oncology
  • Scripps Laboratories
  • Selexis
  • Serum Institute of India
  • Sgi-Dna
  • Sgs
  • Sino Biological
  • Smc Laboratories, Inc.
  • Sobran
  • Speed Biosystem
  • Sri International
  • Syd Labs
  • Syngene
  • Syrinx Bioanalytics
  • Taconic Biosciences
  • Tcg Lifesciences
  • Texcell
  • Therapure Biopharma
  • Tno
  • Toyobo Co. Ltd.
  • Transcure Bioservices
  • Trenzyme
  • Tribiosciences
  • Trinity Bioactives Limited
  • U-Protein Express Bv
  • Uga Biopharma
  • Vifor Pharma Ltd
  • Vipragen Biosciences Pvt Ltd.
  • Viva Biotech Ltd
  • Vivebiotech S.L.
  • Waisman Clinical Biomanufacturing
  • William Harvey Research Limited
  • Woodland Biosciences
  • Wuxi Apptec
  • Xcellerex
  • Yumab
  • Zymeworks Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll